Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine

被引:0
作者
Vanetti, Claudia [1 ]
Stracuzzi, Marta [2 ]
Crivellaro, Elisa [2 ]
Ciciliano, Federica [1 ]
Garziano, Micaela [1 ,3 ]
Fenizia, Claudio [1 ,3 ]
Biasin, Mara [1 ]
Rubinacci, Valeria [2 ]
Amendola, Antonella [4 ]
Tanzi, Elisabetta [4 ]
Zuccotti, Gian Vincenzo [5 ]
Clerici, Mario [3 ,6 ]
Trabattoni, Daria [1 ]
Giacomet, Vania [2 ]
机构
[1] Univ Milan, Dept Biomed & Clin Sci, Milan, Italy
[2] Univ Milan, Osped L Sacco, Pediat Infect Dis Unit, Milan, Italy
[3] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy
[4] Univ Milan, Dept Hlth Sci, Milan, Italy
[5] Osped Bambini V Buzzi, Dept Pediat, Milan, Italy
[6] IRCCS Fdn Don Carlo Gnocchi, Milan, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 14卷
关键词
PLWH; SARS-CoV-2 vaccine efficacy; immunocompromised subjects; COVID-19 SIV individuals; immune response; HEPATITIS-B VACCINATION; INFLUENZA VACCINATION; DOUBLE-BLIND; DEFENSE; ADULTS;
D O I
10.3389/fimmu.2023.1301766
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Data on the efficacy of three SARS-CoV-2 mRNA BNT162b2 vaccine doses and the role of previous SARS-CoV-2-infection in enhancing vaccine immunogenicity in HIV-vertically-infected people living with HIV (PLWH) are limited, as is the duration of vaccine-induced responses. Methods: SARS-CoV-2 plasma neutralizing activity (NA) against the European (B.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants and cell-mediated immunity (CMI) were analyzed in 29 ART-treated young PLWH (mean age 27.9 years) and 30 healthy controls (HC) who received three BNT162b2 vaccine doses. Individuals were stratified based on the presence/absence of previous SARS-CoV-2 infection (infected and vaccinated -SIV-; uninfected and vaccinated -SV-). Analyses were performed before vaccination (T0), 25 days from the second dose (T1), the day the third dose was administered (T2), and 3 months after the third dose (T3). Results: In PLWH: i) NA against all variants was higher in SIV compared to SV at T2 and was increased at T3; ii) switched-memory plasmablasts were augmented in SIV alone at T2 and T3; iii) a SARS-CoV-2 specific T cell memory was generated; iv) IFN-gamma-secreting CD4+ and CD8+ T lymphocytes were boosted at T3 mainly in SV. CMI magnitude was reduced in PLWH compared to HC. Notably, after the third dose of vaccine viremia was unmodified, but CD4 T cell counts were reduced>20% in 3/29 PHLW. Conclusion: A third dose of BNT162b2 vaccine induces strong humoral and CMI responses in young ART-treated PLWH independently from a previous SARS-CoV-2 natural infection. The lower magnitude of CMI responses should be considered when planning mRNA vaccine booster doses in PLWH.
引用
收藏
页数:14
相关论文
共 61 条
[1]   Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan [J].
Akaishi, Tetsuya ;
Kushimoto, Shigeki ;
Katori, Yukio ;
Sugawara, Noriko ;
Egusa, Hiroshi ;
Igarashi, Kaoru ;
Fujita, Motoo ;
Kure, Shigeo ;
Takayama, Shin ;
Abe, Michiaki ;
Kikuchi, Akiko ;
Ohsawa, Minoru ;
Ishizawa, Kota ;
Abe, Yoshiko ;
Imai, Hiroyuki ;
Inaba, Yohei ;
Iwamatsu-Kobayashi, Yoko ;
Nishioka, Takashi ;
Onodera, Ko ;
Ishii, Tadashi .
SCIENTIFIC REPORTS, 2022, 12 (01)
[2]   Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses [J].
Almendro-Vazquez, Patricia ;
Chivite-Lacaba, Marta ;
Utrero-Rico, Alberto ;
Gonzalez-Cuadrado, Cecilia ;
Laguna-Goya, Rocio ;
Moreno-Batanero, Miguel ;
Sanchez-Paz, Laura ;
Luczkowiak, Joanna ;
Labiod, Nuria ;
Dolores Folgueira, Maria ;
Delgado, Rafael ;
Paz-Artal, Estela .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[3]  
Alrubayyi A, 2021, NAT COMMUN, V12, DOI [10.1038/s41467-021-26137-7, 10.1101/2021.02.15.431215]
[4]  
Andreano E., 2022, Immunology, V14, P53, DOI [10.1101/2022.05.09.491201, DOI 10.1101/2022.05.09.491201]
[5]   CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients [J].
Avelino-Silva, Vivian I. ;
Miyaji, Karina T. ;
Hunt, Peter W. ;
Huang, Yong ;
Simoes, Marisol ;
Lima, Sheila B. ;
Freire, Marcos S. ;
Caiaffa-Filho, Helio H. ;
Hong, Marisa A. ;
Costa, Dayane Alves ;
Dias, Juliana Zanatta C. ;
Cerqueira, Natalia B. ;
Nishiya, Anna Shoko ;
Sabino, Ester Cerdeira ;
Sartori, Ana M. ;
Kallas, Esper G. .
PLOS NEGLECTED TROPICAL DISEASES, 2016, 10 (12)
[6]   Omicron: increased transmissibility and decreased pathogenicity [J].
Balint, Gabor ;
Voros-Horvath, Barbara ;
Szechenyi, Aleksandar .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
[7]  
Biasin Mara, 2022, J Photochem Photobiol, V10, P100107, DOI 10.1016/j.jpap.2021.100107
[8]   Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression [J].
Bobrovitz, Niklas ;
Ware, Harriet ;
Ma, Xiaomeng ;
Li, Zihan ;
Hosseini, Reza ;
Cao, Christian ;
Selemon, Anabel ;
Whelan, Mairead ;
Premji, Zahra ;
Issa, Hanane ;
Cheng, Brianna ;
Abu Raddad, Laith J. ;
Buckeridge, David L. ;
Van Kerkhove, Maria D. ;
Piechotta, Vanessa ;
Higdon, Melissa M. ;
Wilder-Smith, Annelies ;
Bergeri, Isabel ;
Feikin, Daniel R. ;
Arora, Rahul K. ;
Patel, Minal K. ;
Subissi, Lorenzo .
LANCET INFECTIOUS DISEASES, 2023, 23 (05) :556-567
[9]   Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272 [J].
Bozzi, Giorgio ;
Lombardi, Andrea ;
Ludovisi, Serena ;
Muscatello, Antonio ;
Manganaro, Lara ;
Cattaneo, Dario ;
Gori, Andrea ;
Bandera, Alessandra .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 113 :125-126
[10]   Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine [J].
Brichacek, B ;
Swindells, S ;
Janoff, EN ;
Pirruccello, S ;
Stevenson, M .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1191-1199